JP2012531195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012531195A5 JP2012531195A5 JP2012516841A JP2012516841A JP2012531195A5 JP 2012531195 A5 JP2012531195 A5 JP 2012531195A5 JP 2012516841 A JP2012516841 A JP 2012516841A JP 2012516841 A JP2012516841 A JP 2012516841A JP 2012531195 A5 JP2012531195 A5 JP 2012531195A5
- Authority
- JP
- Japan
- Prior art keywords
- chromosome
- snp
- gene
- locus
- picalm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000349 chromosome Anatomy 0.000 claims 29
- 210000004027 cell Anatomy 0.000 claims 14
- 108091034117 Oligonucleotide Proteins 0.000 claims 11
- 108091008053 gene clusters Proteins 0.000 claims 11
- 102000003780 Clusterin Human genes 0.000 claims 8
- 108090000197 Clusterin Proteins 0.000 claims 8
- 101000929663 Homo sapiens Phospholipid-transporting ATPase ABCA7 Proteins 0.000 claims 8
- 102100036620 Phospholipid-transporting ATPase ABCA7 Human genes 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 101000583474 Homo sapiens Phosphatidylinositol-binding clathrin assembly protein Proteins 0.000 claims 6
- 102100031014 Phosphatidylinositol-binding clathrin assembly protein Human genes 0.000 claims 6
- 101150084750 1 gene Proteins 0.000 claims 5
- 101100440171 Homo sapiens CLU gene Proteins 0.000 claims 5
- 101710146921 Myc box-dependent-interacting protein 1 Proteins 0.000 claims 5
- 102000006834 complement receptors Human genes 0.000 claims 5
- 108010047295 complement receptors Proteins 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 238000012360 testing method Methods 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 101150095793 PICALM gene Proteins 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 230000005775 apoptotic pathway Effects 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 230000002121 endocytic effect Effects 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 2
- 239000007790 solid phase Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0911539.5 | 2009-07-03 | ||
| GB0911539A GB0911539D0 (en) | 2009-07-03 | 2009-07-03 | Diagnosis of alzheimer's disease |
| GB0913357.0 | 2009-07-31 | ||
| GB0913357A GB0913357D0 (en) | 2009-07-31 | 2009-07-31 | Diagnosis of alzheimer's disease |
| GB0917326A GB0917326D0 (en) | 2009-10-03 | 2009-10-03 | Diagnosis of alzheimer's disease |
| GB0917326.1 | 2009-10-03 | ||
| PCT/GB2010/001208 WO2011001135A2 (en) | 2009-07-03 | 2010-06-22 | Diagnosis and treatment of alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013164509A Division JP5917460B2 (ja) | 2009-07-03 | 2013-08-07 | アルツハイマー病の診断および治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012531195A JP2012531195A (ja) | 2012-12-10 |
| JP2012531195A5 true JP2012531195A5 (enExample) | 2014-12-04 |
| JP5917395B2 JP5917395B2 (ja) | 2016-05-11 |
Family
ID=43014386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516841A Active JP5917395B2 (ja) | 2009-07-03 | 2010-06-22 | アルツハイマー病の診断および治療 |
| JP2013164509A Active JP5917460B2 (ja) | 2009-07-03 | 2013-08-07 | アルツハイマー病の診断および治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013164509A Active JP5917460B2 (ja) | 2009-07-03 | 2013-08-07 | アルツハイマー病の診断および治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20120122703A1 (enExample) |
| EP (2) | EP2891723B1 (enExample) |
| JP (2) | JP5917395B2 (enExample) |
| CN (2) | CN103409511A (enExample) |
| AU (1) | AU2010267835C1 (enExample) |
| CA (1) | CA2766876C (enExample) |
| NZ (1) | NZ596614A (enExample) |
| WO (1) | WO2011001135A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2891723B1 (en) * | 2009-07-03 | 2017-10-04 | University College Cardiff Consultants Limited | Diagnosis and treatment of Alzheimer's disease |
| WO2011024035A1 (en) * | 2009-08-27 | 2011-03-03 | Institut Pasteur De Lille | Method for determining the risk of occurrence of alzheimer's disease |
| GB201212334D0 (en) | 2012-07-11 | 2012-08-22 | Warwick The | Therapeutic targets for alzheimers disease |
| CN104102839B (zh) * | 2013-11-16 | 2017-10-27 | 西安电子科技大学 | 一种基于多尺度网格曲面形状特征的阿尔茨海默病脑皮层自动分类方法 |
| CN105969885A (zh) * | 2016-06-24 | 2016-09-28 | 江苏雄鸣医药科技有限公司 | 一种阿尔兹海默症的基因诊断试剂盒 |
| CN106978475A (zh) * | 2016-08-17 | 2017-07-25 | 上海易瑞生物科技有限公司 | 一种阿尔茨海默氏病易感基因检测分型试剂盒及其应用 |
| CN106290823A (zh) * | 2016-10-18 | 2017-01-04 | 上海凯璟生物科技有限公司 | 一种阿尔兹海默综合症标志物abca7检测试剂盒和制备方法 |
| US11725232B2 (en) * | 2016-10-31 | 2023-08-15 | The Hong Kong University Of Science And Technology | Compositions, methods and kits for detection of genetic variants for alzheimer's disease |
| US20210293794A1 (en) * | 2017-02-24 | 2021-09-23 | University Of Hawii Cancer Center | Metabolic biomarkers for the identification and characterization of alzheimers disease |
| KR101933847B1 (ko) | 2017-05-15 | 2018-12-28 | 조선대학교산학협력단 | 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도 |
| EP3626830A4 (en) * | 2017-05-15 | 2021-01-27 | Infomeditech Co., Ltd. | SINGLE NUCLEOTIDE POLYMORPHISM OF AN APOE PROMOTER RELATED TO ALZHEIMER'S MORBUS AND USE OF IT |
| WO2018212371A1 (ko) * | 2017-05-17 | 2018-11-22 | 조선대학교산학협력단 | 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도 |
| EP3764902A4 (en) * | 2018-03-13 | 2021-12-08 | I2Dx, Inc. | ELECTRONIC PROVISION OF INFORMATION IN PERSONALIZED MEDICINE |
| EP4520842A3 (en) | 2018-05-18 | 2025-09-10 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| CN110607364B (zh) * | 2019-11-01 | 2023-04-28 | 北京中医药大学 | 通过检测snp位点确定等位基因的基因型的方法 |
| KR102561438B1 (ko) * | 2020-11-04 | 2023-07-28 | 사회복지법인 삼성생명공익재단 | 뇌 아밀로이드 베타 축적 가능성을 예측하는 방법 |
| JP7731540B2 (ja) * | 2021-03-26 | 2025-09-01 | 国立研究開発法人農業・食品産業技術総合研究機構 | アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット |
| CA3214838A1 (en) * | 2021-04-13 | 2022-10-20 | Haruhisa Inoue | Information processing method, information processing device, and program |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| KR102775636B1 (ko) * | 2022-03-15 | 2025-03-05 | 사회복지법인 삼성생명공익재단 | 유럽 인구 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법 |
| CN114736963B (zh) * | 2022-05-25 | 2023-03-24 | 首都医科大学宣武医院 | 一种用于预测阿尔茨海默病发病风险的物质的组合、试剂盒及应用 |
| KR20250125708A (ko) * | 2024-02-15 | 2025-08-22 | 이화여자대학교 산학협력단 | 고인지예비능 생체표지자로서의 snp 및 이의 이용 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2765591B1 (fr) * | 1997-07-01 | 2002-08-09 | Pasteur Institut | Procede de diagnostic de la maladie d'alzheimer |
| WO2006138716A2 (en) * | 2005-06-17 | 2006-12-28 | Brt Laboratories, Inc. | Thermodynamically defined gene specific primers |
| JP2007166962A (ja) * | 2005-12-21 | 2007-07-05 | Japan Health Science Foundation | アルツハイマー病の予測または診断の方法 |
| WO2008085601A2 (en) * | 2006-11-02 | 2008-07-17 | Genizon Biosciences Inc. | Genemap of the human genes associated with asthma disease |
| MX2009011079A (es) * | 2007-04-17 | 2010-03-10 | Kei Tashiro | Metodo para la determinacion del riesgo del inicio de glaucoma. |
| EP2891723B1 (en) * | 2009-07-03 | 2017-10-04 | University College Cardiff Consultants Limited | Diagnosis and treatment of Alzheimer's disease |
-
2010
- 2010-06-22 EP EP15152097.0A patent/EP2891723B1/en active Active
- 2010-06-22 CA CA2766876A patent/CA2766876C/en active Active
- 2010-06-22 CN CN2013102808899A patent/CN103409511A/zh active Pending
- 2010-06-22 US US13/376,485 patent/US20120122703A1/en not_active Abandoned
- 2010-06-22 JP JP2012516841A patent/JP5917395B2/ja active Active
- 2010-06-22 EP EP10747062.7A patent/EP2449134B1/en active Active
- 2010-06-22 NZ NZ59661410A patent/NZ596614A/xx unknown
- 2010-06-22 CN CN2010800292599A patent/CN102471800A/zh active Pending
- 2010-06-22 WO PCT/GB2010/001208 patent/WO2011001135A2/en not_active Ceased
- 2010-06-22 AU AU2010267835A patent/AU2010267835C1/en active Active
-
2013
- 2013-05-03 US US13/886,473 patent/US20130288906A1/en not_active Abandoned
- 2013-08-07 JP JP2013164509A patent/JP5917460B2/ja active Active
-
2014
- 2014-04-14 US US14/252,153 patent/US20150119264A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012531195A5 (enExample) | ||
| JP2014012007A5 (enExample) | ||
| Yamagishi et al. | Mechanisms of action and resistance in histone methylation-targeted therapy | |
| Craig et al. | RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson’s disease | |
| Heikkinen et al. | The potential of DNA methylation as a biomarker for obesity and smoking | |
| Quinn et al. | Extracellular RNAs: development as biomarkers of human disease | |
| Chinnery et al. | Epigenetics, epidemiology and mitochondrial DNA diseases | |
| Numata et al. | Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles: discovery and validation | |
| Song et al. | Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder | |
| Ivanova et al. | What did we learn from multiple omics studies in asthma? | |
| Hachiya et al. | Genome-wide identification of inter-individually variable DNA methylation sites improves the efficacy of epigenetic association studies | |
| Alfirevic et al. | Predictive genetic testing for drug‐induced liver injury: considerations of clinical utility | |
| Dengu | Next-generation sequencing methods to detect donor-derived cell-free DNA after transplantation | |
| Hong et al. | Epigenetics and development of food allergy (FA) in early childhood | |
| JP2010538680A5 (enExample) | ||
| TW200844238A (en) | HLA alleles associated with adverse drug reactions and methods for detecting such | |
| Kidambi et al. | Non-replication study of a genome-wide association study for hypertension and blood pressure in African Americans | |
| Sabunciyan et al. | Association of DNA methylation with acute mania and inflammatory markers | |
| Zhang et al. | Altered DNA methylation within DNMT3A, AHRR, LTA/TNF loci mediates the effect of smoking on inflammatory bowel disease | |
| Verma et al. | Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling | |
| WO2007123233A1 (ja) | 動脈硬化性疾患関連遺伝子、およびその利用 | |
| Clark et al. | Dual methylation and hydroxymethylation study of alcohol use disorder | |
| Mendrick | Transcriptional profiling to identify biomarkers of disease and drug response | |
| Johnson et al. | The Cure VCP Scientific Conference 2021: molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1) | |
| KR101604178B1 (ko) | 약물에 의한 간 손상의 예측 및 진단을 위한 바이오마커 |